Introduction: The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods: In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m2 intravenously every 3 weeks as part of a 21-day cycle for 6 cycles. Restaging studies to assess response were performed after cycles 2 and 6, and every three months thereafter. Results: Between July 2007 and January 2009, 20 patients were enrolled. Baseline characteristics were as follows: 65% had prior adjuvant chemotherapy, 55% had prior chemotherapy for metastatic breast cancer; mean age was 48 years (ranges 32 to 70); 30% estrogen receptor (ER) or progesterone receptor (PR)+, 70% ER/PR/Human Epidermal Growth Factor Receptor 2 (HER2)- and 0% HER2+. Overall response rate was 80%; nine patients experienced a complete clinical response (45%) and seven experienced a partial response (35%). Overall survival was 80% at one year, 60% at two years and 25% at three years. Four of the 20 patients are alive four years after initiating treatment. The median time to progression was 12 months. The median survival from the start of cisplatinum treatment was 30 months. Cisplatin-related adverse events, including nausea (50%), anemia (5%) and neutropenia (35%) were mostly mild to moderate in severity. Conclusions: This phase II study demonstrates that cisplatin chemotherapy has high activity in women with a BRCA1 mutation and metastatic breast cancer and is generally well tolerated. Trial registration: This trial is registered retrospectively on the clinical trials website ClinicalTrials.gov. The identifier is NCT01611727.
Most patients with large focal skull bone loss after craniectomy are referred for cranioplasty. Reverse engineering is a technology which creates a computer-aided design (CAD) model of a real structure. Rapid prototyping is a technology which produces physical objects from virtual CAD models. The aim of this study was to assess the clinical usefulness of these technologies in cranioplasty prosthesis manufacturing. CT was performed on 19 patients with focal skull bone loss after craniectomy, using a dedicated protocol. A material model of skull deficit was produced using computer numerical control (CNC) milling, and individually pre-operatively adjusted polypropylene-polyester prosthesis was prepared. In a control group of 20 patients a prosthesis was manually adjusted to each patient by a neurosurgeon during surgery, without using CT-based reverse engineering/rapid prototyping. In each case, the prosthesis was implanted into the patient. The mean operating times in both groups were compared. In the group of patients with reverse engineering/rapid prototyping-based cranioplasty, the mean operating time was shorter (120.3 min) compared to that in the control group (136.5 min). The neurosurgeons found the new technology particularly useful in more complicated bone deficits with different curvatures in various planes. Reverse engineering and rapid prototyping may reduce the time needed for cranioplasty neurosurgery and improve the prosthesis fitting. Such technologies may utilize data obtained by commonly used spiral CT scanners. The manufacturing of individually adjusted prostheses should be commonly used in patients planned for cranioplasty with synthetic material.
Background: For decades, the main imaging tool in multiple myeloma (MM) patients was plain radiography. However, computed tomography (CT) has been included in the updated criteria of MM. The main disadvantage of CT is a considerably high radiation dose. Therefore, low-dose CT protocols could be a solution. The aim of the study was to (1) preliminarily analyse the usefulness of Whole-Body Low-Dose CT (WBLDCT) in the evaluation of patients with MM and (2) to make adjustments in the standard CT imaging protocol. Material/Methods: In 41 patients with MM, WBLDCT was performed. The following parameters were used: detector configuration – 80×0.5 mm, scanning range in a single spiral acquisition from the skull to the proximal femoral bones, tube voltage – 120 kVp, current tube time product – 86 mAs, slice thickness 1 mm. Two sets of axial images were reconstructed for bone and soft tissue assessment, respectively. Secondary coronal and sagittal reconstructions were generated. Typical MM features were analysed and qualitatively compared with radiography results. Results: A potentially increased sensitivity of CT, as compared to radiography, in detecting lytic foci obscured by other structures or with a small degree of destruction was seen. A potentially increased specificity of CT was found in detecting cases of small foci suspicious of lytic lesions on skull radiographs, seen as arachnoid granulations fovea in CT. The following radiation parameters were recorded: max. CTDIvol – 7.4 mGy and DLP – 660–810 mGy×cm. WBLDCT was much shorter and more convenient to patients. Conclusions: WBLDCT may become a valuable part of the assessment of MM features at a much lower radiation dose compared to standard CT protocols. It has a potential ability to increase diagnostic accuracy compared to radiography.
1 January 2017 in Neurologia i Neurochirurgia Polska
In patients with ischemic stroke involving MCA region and no early signs of brain tissue ischemia on the admission CT, HMCAS is associated with significantly lower ASPECTS in the follow-up CT. There is moderate correlation between the length of hyperdense MCA segment and ASPECTS.
1 September 2017 in Neurologia i Neurochirurgia Polska
The aim of the study was to find how to differentiate hyperdense middle cerebral artery sign (HMCAS) in stroke patients from asymmetric hyperdensity not related to stroke, by comparison of the CT density values typical for HMCAS to the values in normal or atherosclerotic middle cerebral artery (MCA). The group analyzed consisted of 100 patients with ischemic stroke, presenting HMCAS on the admission CT. Density measurements in HU were performed in the hyperdense segment of the involved MCA, contralateral MCA, brain cortex adjacent to the hyperdense MCA. The control group consisted of 100 patients with no symptoms of cerebral stroke. Density measurements in HU were performed: in the M1 segment of right and left MCA, brain cortex adjacent to the more dense from right or left MCA. In the stroke group the median values obtained were: in the hyperdense MCA 59 HU, contralateral MCA 41 HU, brain cortex 36 HU. In the control group the median values obtained were: in the more dense MCA 43 HU, contralateral MCA 40 HU, brain cortex 34 HU. The range of HMCAS/contralateral MCA density ratios in stroke only slightly overlapped the range of more dense MCA/contralateral MCA density ratios in non-stroke patients. The ratio of hyperdense MCA CT density/contralateral density is a good tool to differentiate HMCAS from asymmetric hyperdensity not related to stroke. The threshold ≥1.16 provided 100% sensitivity and 97% specificity, whereas ≥1.22 provided 94% sensitivity and 100% specificity.